APA. A. Polyakov

A. A. Polyakov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. A. Polyakov has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Полина Александровна Лушникова

    Scientific Research Institute of Oncology — branch of Tomsk National Medical Research Centre, Russian Academy of Sciences; Tomsk Regional Oncology Dispensary

    5 shared publications
  • Olga V. Gribova

    Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

    4 shared publications
  • Viktoria Velikaya

    Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

    3 shared publications
  • Zhanna A. Startseva

    Tomsk National Research Medical Center of the Russian Academy of Sciences

    3 shared publications
  • А. А. Поляков

    Научно-исследовательский институт онкологии — филиал Томского национального исследовательского медицинского центра Российской академии наук; Томский областной онкологический диспансер

    2 shared publications
  • В. В. Великая

    Научно-исследовательский институт онкологии — филиал Томского национального исследовательского медицинского центра Российской академии наук

    2 shared publications

Latest Publications

  • Open Access

    Malignant Tumors of the Uterine Corpus in the Era of Molecular Oncology: How Mutations Change Approaches to Adjuvant Treatment

    by P. A. Lushnikova, Zh. A. Startseva, A. A. Polyakov, A. V. Taletskiy, V. V. Velikaya, O. V. Gribova, П. А. Лушникова, Ж. А. Старцева, А. А. Поляков, А. В. Талецкий, et al.

    Four currently known main molecular subtypes of endometrial cancer include tumors with POLE and p53 protein mutations, with a defective mismatch repair system, as well as without a specific molecular profile. The molecular classification of malignant tumors can be used to predict the course of the disease and determine the need for adjuvant treatment. Patients with POLE mutations often require no adjuvant treatment and have a favorable prognosis for overall and disease-free survival, while patients with p53 protein mutations require aggressive adjuvant treatment due to high rates of disease progression. Women with p53 protein mutations benefit most from adding chemotherapy to adjuvant treatment. Tumors with microsatellite instability and without a specific molecular subtype have an intermediate prognosis: the need for adjuvant treatment is determined by the extent of the disease. Moreover, the addition of immune therapy for metastatic cancer in patients with microsatellite instability brings benefits to survival rates. Knowing the molecular subtype of endometrial cancer can make treatment more personalized and improve targeting of radiation, immune, and drug therapy after surgery.

  • Open Access

    Optimization of radiotherapy as a strategy for preventing capsular contracture after skin-sparing mastectomy with implant-based reconstruction

    by A. A. Polyakov, V. V. Velikaya, Zh. A. Startseva, P. A. Lushnikova, D. M. Podoplekin, O. V. Gribova, А. А. Поляков, В. В. Великая, Ж. А. Старцева, П. А. Лушникова, et al.

    Objective. To analyze current evidence on the impact of radiation therapy on the risk of capsular contracture in patients undergoing nipple-sparing and skin-sparing mastectomy with immediate implant-based reconstruction, and to evaluate strategies for optimizing radiation delivery in order to reduce reconstructive complications without compromising oncologic outcomes. Materials and methods. A review of randomized clinical trials, prospective and retrospective cohort studies, as well as dosimetric analyses addressing radiation therapy in patients after nipple-sparing and skin-sparing mastectomy with immediate implant-based reconstruction was performed. The literature search was conducted in PubMed, Cochrane Library, Elsevier, and eLIBRARY. RU databases. Data regarding the incidence of capsular contracture, clinical and dosimetric risk factors, the impact of radiation target volumes, fractionation schedules, planning techniques (3D-CRT, IMRT, VMAT), the use of deep inspiration breath hold (DIBH), and implant-specific dose constraints were analyzed. Results. The incidence of clinically significant capsular contracture following radiation therapy ranges from 15 % to 30 % and depends on a combination of surgical, clinical, and radiation-related factors. Radiation dose delivered to the implant and surrounding tissues, including Dmean and Dmax parameters, appears to be a potential predictor of fibrotic changes. Individualization of clinical target volumes, justified de-escalation of regional nodal irradiation in selected clinical scenarios, the use of hypofractionation, advanced planning techniques (IMRT / VMAT), implementation of DIBH, and application of implant dose constraints may reduce the risk of late complications while maintaining adequate target coverage. Conclusions. Optimization of radiation therapy planning and delivery after nipple-sparing and skin-sparing mastectomy with immediate implant-based reconstruction using modern technologies, individualization of target volumes and fractionation schedules, and careful control of dose to the implant may minimize the risk of capsular contracture without compromising oncologic outcomes. Further prospective studies are required to refine dose constraints and develop standardized clinical recommendations.

  • The contribution of radiation therapy in the treatment of endometrial cancer

    by P.A. Lushnikova, Zh.A. Startseva, A.A. Polyakov, V.V. Velikaya, I.B. Pyzhova, A.V. Taletsky, O.V. Gribova

    Endometrial cancer (EC) is a fairly common disease in the female population today. The main treatment is surgery. However, in some cases, patients need combined treatment: surgery in combination with a course of remote radiation therapy, brachytherapy or courses of drug treatment. Adjuvant treatment in these cases is prescribed in the presence of risk factors for disease progression and is necessary to increase overall and disease-free survival in patients with EC. For the correct prescription of adjuvant therapy, radiotherapists should know the risk factors for the progression of endometrial cancer after surgery and follow generally accepted clinical guidelines in the treatment of this pathology. It is unacceptable to currently prescribe adjuvant treatment unreasonably, and at the same time, risk factors for progression cannot be ignored. This article demonstrates possible risk factors for progression in patients with ER after surgical treatment and shows the adjuvant treatment regimens that are necessary for this group of patients.

  • Open Access

    Analysis of Target Coverage Variability and Compliance with Tolerant Doses Using a Fixed Dosimetric Plan for Intracavitary Radiation Therapy for Cervical Cancer. Tomsk City Oncology Center Experience

    by Полина Александровна Лушникова, Жанна Александровна Старцева, Алексей Александрович Поляков, Анастасия Евгеньевна Арышева, Евгения Сергеевна Сухих, Ирина Борисовна Пыжова, Виктория Валерьевна Великая, Ольга Вячеславовна Грибова

    Введение. При местнораспространенной стадии рака шейки матки применяется лучевая терапия. Лечение состоит из дистанционного курса химиолучевой терапии и последующего брахитерапевтического буста. Второй этап радиотерапии главным образом сказывается на результате локального контроля, поэтому важно соблюдать все требования данного лечения. Цель. В некоторых онкологических центрах во время проведения этапа внутриполостной брахитерапии используется первоначальный фиксированный план лечения, разработанный во время первой процедуры. Целью данной работы является анализ применимости дозиметрического плана первой фракции внутриполостной брахитерапии для последующих фракций без перепланирования с учетом наиболее важных характеристик дозиметрического плана: охвата объема облучения (опухоли) предписанной дозой и соблюдения ограничений лучевых нагрузок на органы риска. Материалы и методы. В исследование были включены 10 пациенток с диагнозом местнораспространенный рак шейки матки IIА-IIIC стадии, проанализированы 42 плана брахитерапии для каждой фракции облучения. Результаты. У 9 из 10 пациенток применение дозиметрического плана лечения первой фракции для последующих фракций с учетом охвата объема облучения (опухоли) предписанной поглощенной дозой было допустимо. У одной пациентки наблюдалось «недооблучение» объема опухолевого процесса в связи с большим объемом поражения (опухолевая инфильтрация тела матки). Со стороны превышения толерантных уровней лучевых нагрузок для органов риска получены следующие результаты: превышение допустимой дозы на мочевой пузырь у одной пациентки на втором и на третьем сеансе облучения, что привело к перепланированию лечения; превышение нагрузки на сигмовидную кишку у четырех пациенток, что также потребовало корректировки дозиметрического плана. У половины больных наблюдались незначительные превышения допустимых лучевых нагрузок на петли кишечника во время проведения курса брахитерапии. Выводы. Использование фиксированного плана лечения возможно, но только в случае небольшого объема облучения (не более 30-33 см3), при удаленном положении органов риска от источника облучения, удовлетворительном комплаенсе с пациенткой и уверенности в ее соблюдении рекомендаций врача по подготовке к сеансам лечения.

  • Open Access

    Primary refractory Ewing sarcoma of the chest wall in an adult patient (case report). The potential and role of radiation therapy

    by А. А. Polyakov, P. А. Lushnikova

       Introduction: Ewing sarcoma is the second most common bone tumor, behind osteosarcoma, and is the most common bone tumor among children under 15 years of age. Quite rarely, these tumors occur in patients over 30 years of age and under 5 years of age. Ewing sarcoma of the chest wall is a rare malignant neoplasm, which is rarely reported in the scientific literature. An integrated approach combining chemotherapy, surgery, and radiation therapy is commonly used in the treatment of this neoplasm. However, there is no standard treatment for this tumor when the disease progresses during the first-line treatment. Although modern combined approaches to treatment, including chemotherapy, surgery, and radiation therapy, help achieve disease control in some patients, the lack of standardized protocols for the treatment of refractory and recurrent forms results in significant difficulties in determining optimal therapeutic options. In real-world clinical practice, physicians have limited personal experience in managing such patients, which leads to variability in the chosen treatment plans for refractory disease and the need to make decisions based on limited data. The article discusses the main approaches to the treatment, as well as the potential and role of radiation therapy in the treatment of this disease and presents a case report of unresectable Ewing sarcoma of the chest wall in a 50-year-old male patient with local progression during first-line chemotherapy.

  • Open Access

    What we know about the new coronavirus infection in cancer patients

    by P. S. Feoktistova, E. A. Azarova, D. M. Volkova, A. A. Emelyanova, A. K. Iglamov, A. N. Igumnova, A. Z. Isyangulova, M. S. Mazhbich, K. V. Menshikov, Yu. I. Murzina, et al.

    The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.


  • Open Access

    Clinical experience of using the radium-223 in patients with bone metastasis of castration-resistant prostate cancer

    by Z. A. Yurmazov, E. A. Usynin, A. A. Medvedeva, A. A. Polyakov, N. A. Lushnikova, V. I. Chernov, L. V. Spirina

    Background. Prostate cancer is one of the actual problems of modern oncology. The incidence of prostate cancer is steadily increasing despite of popularization of screening and early diagnostics. It is worth to highlight separately the castration-resistant prostate cancer which develops on the average 2 years after surgical or medicinal castration. For the patients with metastatic castration-resistant prostate cancer (mCRPC) the main purpose of treatment is increasing of overall survival while maintaining the quality of life. Currently there are several treatment options for mCRPC: chemotherapy, inhibitors of androgen receptor pathway,systemic alfa-radiotherapy, PARP-inhibitorsfor homologousrecombination DNA repair deficiency. Using of several sequential lines of mCRPC therapy leads to maintaining the patients’ quality of life and increasing its duration. Systemic alfa-radiotherapy is using since 2013 – the first is radium-223 which was approved by Food and Drug Administration according the results of the phase III trial ALSYMPCA. In Russian Federation radium-223 was approved in 2016.Objective: to evaluate the efficiency and safety oftherapy with radium-223 as well as pain response at patients with mCRPC.Materials and methods. 67 patients were included in this analysis who received radium-223 therapy at Scientific Research Institute of Tomsk National Research Medical Center of Russian Academy of Sciences and Tomsk Regional Oncology Dispensary.Results and conclusion. Radium-223 has demonstrated its efficiency for mCRPC patients with good safety profile and positive pain response and maintaining the QoL.